Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)
Clinical trial NCT03221426 · COMPLETED
Trial details
- NCT number
- NCT03221426
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- COMPLETED
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2017-10-09
- Primary completion
- 2024-02-16
- Enrollment
- 1007
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.